Get the Stockscreener App
681.85
2.70%
17.92
Pre-market:
686.28
4.43
+0.65%
Argen X Se Adr stock is traded at $681.85, with a volume of 391.05K.
It is up +2.70% in the last 24 hours and down -17.48% over the past month.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
See More
Previous Close:
$663.93
Open:
$684.98
24h Volume:
391.05K
Relative Volume:
1.10
Market Cap:
$42.32B
Revenue:
$4.16B
Net Income/Loss:
$1.29B
P/E Ratio:
34.82
EPS:
19.5837
Net Cash Flow:
$734.26M
1W Performance:
-3.05%
1M Performance:
-17.48%
6M Performance:
-7.15%
1Y Performance:
+10.87%
1-Day Range:
$678.67
$692.90
1-Week Range:
$661.85
$716.25
52-Week Range:
$510.06
$934.62
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
681.85 | 42.32B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
451.24 | 114.63B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
736.53 | 77.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
306.66 | 40.67B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
143.98 | 31.04B | 606.42M | -1.28B | -997.58M | -6.403 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-18-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-24-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-15-25 | Resumed | Truist | Buy |
| Sep-11-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-08-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-13-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-17-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-12-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-17-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Strong Buy |
| Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jul-25-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-31-23 | Initiated | Scotiabank | Sector Perform |
| Jul-24-23 | Downgrade | UBS | Buy → Neutral |
| Jul-17-23 | Resumed | Evercore ISI | Outperform |
| Jun-15-23 | Initiated | Societe Generale | Sell |
| May-31-23 | Initiated | UBS | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-07-22 | Initiated | William Blair | Outperform |
| Oct-12-22 | Initiated | Oppenheimer | Perform |
| Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-22 | Resumed | Stifel | Buy |
| May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-23-21 | Initiated | Deutsche Bank | Hold |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-18-21 | Initiated | UBS | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-23-21 | Initiated | Redburn | Neutral |
| Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
| Feb-10-20 | Initiated | BofA/Merrill | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-22-19 | Initiated | JP Morgan | Overweight |
| Sep-27-19 | Initiated | Wells Fargo | Market Perform |
| Sep-16-19 | Resumed | Cowen | Outperform |
| Jun-28-19 | Initiated | Robert W. Baird | Outperform |
| Jan-18-19 | Resumed | SunTrust | Buy |
| Jan-04-19 | Initiated | Morgan Stanley | Overweight |
| Dec-17-18 | Initiated | Goldman | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Jun-29-18 | Initiated | Nomura | Buy |
| Apr-09-18 | Initiated | SunTrust | Buy |
| Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story - The Motley Fool
Form 6K argenx NV ADR For: 20 March - Investing.com
argenx announces Annual General Meeting of Shareholders on May 6, 2026 - ChartMill
ARGX Stock Price, Quote & Chart | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Argenx SE stock faces pressure as Iron Triangle Partners trims position amid biotech sector watchlis - AD HOC NEWS
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today - Sahm
TD Cowen reiterates argenx stock Buy rating on growth outlook By Investing.com - Investing.com India
TD Cowen reiterates argenx stock Buy rating on growth outlook - Investing.com
Deutsche Bank lifts Argenx to Buy as valuation ’no longer demanding’ - Investing.com South Africa
Deutsche Bank upgrades argenx stock to Buy on valuation appeal - Investing.com South Africa
Forecasting The Future: 16 Analyst Projections For argenx - Sahm
Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached - Finviz
Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock - Finviz
Argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - marketscreener.com
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - ChartMill
Empowering Investor Success - Morningstar
Argenx Benefits From Strong Growth for Vyvgart; Pipeline Continues to Make Progress - Morningstar
Oppenheimer raises argenx stock price target to $1,060 on sales growth - Investing.com
RBC Capital Adjusts argenx SE ADR PT to $890 From $925, Maintains Outperform Rating - marketscreener.com
ARGENX : Goldman Sachs gives a Buy rating - marketscreener.com
Citizens raises argenx stock price target on ocular MG results - Investing.com
ARGENX : Deutsche Bank reiterates its Neutral rating - marketscreener.com
argenx Q4 2025 slides: first profitable year, 90% revenue surge By Investing.com - Investing.com Australia
Stifel cuts argenx stock price target to $1,227 on valuation By Investing.com - Investing.com South Africa
Earnings call transcript: Argenx Q4 2025 sees strong earnings beat, stock dips - Investing.com
BofA raises argenx stock price target to $1,013 on trial success - Investing.com
Stifel cuts argenx stock price target to $1,227 on valuation - Investing.com India
argenx Q4 2025 slides: first profitable year, 90% revenue surge - Investing.com South Africa
ARGENX : Gets a Buy rating from Goldman Sachs - marketscreener.com
ARGENX : Barclays reiterates its Buy rating - marketscreener.com
Argenx's Vyvgart Improves Ocular Myasthenia Gravis Symptoms in Late-stage Trial - marketscreener.com
ARGENX : Receives a Buy rating from Bernstein - marketscreener.com
Argenx reports $1.3 billion in Q4 global product net sales - marketscreener.com
Argenx: Positive topline results from phase 3 adapt oculus trial of Vyvgart in oMG - marketscreener.com
argenx ADR earnings beat by $2.07, revenue topped estimates - Investing.com
Argenx Says Phase 3 Study of Ocular Myasthenia Gravis Therapy Met Main Goal - marketscreener.com
Argenx SE FY25 swings to profit as Vyvgart sales double - Investing.com
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Argenx Reports Higher FY25 Attributable Profit, Operating Income - marketscreener.com
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update - Sahm
Insights into argenx's Upcoming Earnings - Sahm
Artisan Mid Cap Fund Maintains Its Confidence in Argenx’s (ARGX) VYVGART - Insider Monkey
argenx to Present at TD Cowen 46th Annual Healthcare Conference - ChartMill
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026 - Sahm
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues - Finviz
Increased Demand for Vyvgart Boosted Argenx SE (ARGX) in Q4 - Insider Monkey
Analysts May Have Underestimated Argenx SE's (ARGX) 5 year Revenue Growth - Finviz
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
5.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):